Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/113663
Title: | Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer : final results of the AIO CHARTA trial |
Author(s): | Schmoll, Hans-Joachim![]() Meinert, Fabian Rüssel, Jörn ![]() Cygon, Franziska Steighardt, Jörg [und viele weitere] |
Issue Date: | 2024 |
Type: | Article |
Language: | English |
Abstract: | Background: FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria. Methods: The AIO “CHARTA” trial randomised mCRC patients into clinical Group 1 (potentially resectable), 2 (unresectable/risk of rapid progression), or 3 (asymptomatic). They received FOLFOX/bevacizumab +/− irinotecan. The primary endpoint was the 9-month progression-free survival rate (PFSR@9). Secondary endpoints included efficacy in stratified groups, QoL, PFS, OS, ORR, secondary resection rate, and toxicity. Results: The addition of irinotecan to FOLFOX/bevacizumab increased PFSR@9 from 56 to 67%, meeting the primary endpoint. The objective response rate was 61% vs. 69% (P = 0.21) and median PFS was 10.3 vs. 12 months (HR 0.83; P = 0.17). The PFS was (11.4 vs. 12.9 months; HR 0.83; P = 0.46) in potentially resectable patients, with a secondary resection rate of 37% vs. 51%. Moreover, Group 3 (asymptomatic) patients had a PFS of 11.1 vs. 16.1 months (HR 0.6; P = 0.14). The addition of irinotecan did not diminish QoL. Conclusion: The CHARTA trial, along with other studies, confirms the efficacy and tolerability of FOLFOXIRI/bevacizumab as a first-line treatment for mCRC. Importantly, clinical stratification may lead to its implementation. |
URI: | https://opendata.uni-halle.de//handle/1981185920/115618 http://dx.doi.org/10.25673/113663 |
Open Access: | ![]() |
License: | ![]() |
Journal Title: | British journal of cancer |
Publisher: | Nature Publ. Group |
Publisher Place: | Edinburgh |
Volume: | 130 |
Original Publication: | 10.1038/s41416-023-02496-4 |
Page Start: | 233 |
Page End: | 241 |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s41416-023-02496-4.pdf | 920.05 kB | Adobe PDF | ![]() View/Open |